Integrated genomics approach to identify biologically relevant alterations in fewer samples by unknown
Chandrani et al. BMC Genomics  (2015) 16:936 
DOI 10.1186/s12864-015-2138-4RESEARCH ARTICLE Open AccessIntegrated genomics approach to identify
biologically relevant alterations in fewer
samples
Pratik Chandrani1, Pawan Upadhyay1, Prajish Iyer1, Mayur Tanna1, Madhur Shetty1, Gorantala Venkata Raghuram1,
Ninad Oak1, Ankita Singh1, Rohan Chaubal1, Manoj Ramteke1, Sudeep Gupta2 and Amit Dutt1*Abstract
Background: Several statistical tools have been developed to identify genes mutated at rates significantly higher
than background, indicative of positive selection, involving large sample cohort studies. However, studies involving
smaller sample sizes are inherently restrictive due to their limited statistical power to identify low frequency genetic
variations.
Results: We performed an integrated characterization of copy number, mutation and expression analyses of four
head and neck cancer cell lines - NT8e, OT9, AW13516 and AW8507– by applying a filtering strategy to prioritize for
genes affected by two or more alterations within or across the cell lines. Besides identifying TP53, PTEN, HRAS and
MET as major altered HNSCC hallmark genes, this analysis uncovered 34 novel candidate genes altered. Of these,
we find a heterozygous truncating mutation in Nuclear receptor binding protein, NRBP1 pseudokinase gene,
identical to as reported in other cancers, is oncogenic when ectopically expressed in NIH-3 T3 cells. Knockdown of
NRBP1 in an oral carcinoma cell line bearing NRBP1 mutation inhibit transformation and survival of the cells.
Conclusions: In overall, we present the first comprehensive genomic characterization of four head and neck cancer
cell lines established from Indian patients. We also demonstrate the ability of integrated analysis to uncover
biologically important genetic variation in studies involving fewer or rare clinical specimens.Background
Head and neck squamous cell carcinoma (HNSCC) is
the sixth-most-common cancer worldwide, with about
600,000 new cases every year, and includes cancer of the
nose cavity, sinuses, lips, tongue, mouth, salivary glands,
upper aerodigestive tract and voice box [1]. Recent large
scale cancer genome sequencing projects have identified
spectrum of driver genomic alterations in HNSCC
including CDKN2A, TP53, PIK3CA, NOTCH1, HRAS,
FBXW7, PTEN, NFE2L2, FAT1, and CASP8 [2–4]. These
landmark studies apply elegant statistical methodologies
like MutSig [5], Genome MuSiC [6], Intogen [7], InVEx
[8], ActiveDrive [9] and GISTIC [10] in identifying
significantly altered genes across large sample cohorts
by comparing rate of mutations of each gene with* Correspondence: adutt@actrec.gov.in
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enrichment– a minimum ~150 patients or higher is re-
quired for identification of somatic mutations of 10 %
population frequency in HNSCC [11]. These genome-
wide analysis may not be directly applicable for studies
involving fewer or rare clinical specimen that are inher-
ently restrictive due to the limited statistical power to
detect alterations existing at lower frequency.
On the other hand, given that a cancer gene could be
selectively inactivated or activated by multiple alter-
ations, an integrative study design performed by com-
bining multiple data types can potentially be helpful
to achieve the threshold for statistical significance
for studies involving fewer or rare clinical specimen.
For example, a tumor suppressor gene– deleted in
1 % of patients, mutated in another 3 %, promoter-
hypermethylated in another 2 % and out of frame fused
with some other chromosomal region in 2 %– may be
considered to be altered with a cumulative effect of 8 %icle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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sources of genetic evidence converging at same gene or
signalling pathway can also limit false positives by filter-
ing strategy and potentially reducing the multiple hy-
pothesis testing burden for identification of causal
genotype-phenotype associations [14]. Using similar ap-
proaches for posterior refinement to indicate positive
selection, Pickering et al. identified four key pathways in
oral cancer by integrating methylation to copy number
variation and expression [15]; and, more recently,
Wilkerson et al. proposed superior prioritisation of
mutations based on integrated analysis of the genome
and transcriptome sequencing than filtering based on
conventional quality filters [16]. These and several other
reports all together emphasize integration of multi-
platform genomic data for identification of cancer
related genes [17].
Here, we perform characterization of four head and
neck cancer cell lines, established from Indian head and
neck cancer patients, using classical cytogenetic ap-
proach, SNP arrays, whole exome and whole transcrip-
tome sequencing. Next, we apply the widely used
posterior filtering strategy of results obtained from
genome wide studies to effectively reduce the amount of
data obtained from individual platforms. Adopting such
an integrative approach allow us to identify biological
relevant alterations affected by two or more events even
from fewer samples.
Methods
Cell culturing and single cell dilution for establishing
clonal cells
Four HNSCC tumor cell lines established within Tata
Memorial Center from Indian patients and described
before were acquired: NT8e, OT9, AW13516, AW8507
[18, 19]. All the cell lines were maintained in DMEM
media (Gibco, USA). For clonal selection, growing
culture was trypsinized and diluted as 1 cell per 100 ml
of media and dispensed in a 96 well plate with follow up
subculture of clones that survived.
SNP array analysis
Genomic DNA was extracted from pre-clonal and clonal
cell lines using PAXgene Tissue DNA Kit (Qiagen,
USA). 200 ng of good quality DNA from each sample
was submitted to Sandor Proteomics (Hyderabad, India)
for sample preparation and genome wide SNP array using
Illumina Infinium assay (Human660W-quad BeadArray
chip) following manufacturer’s standard protocol. Array
data was pre-processed using GenomeStudio (Illumina
Inc., USA) for quality control check. To retain only good
quality genotyping calls, a threshold GenCall score of 0.25
was used across all samples. A total of 396, 266 SNPs were
retained after this filtering. These SNPs were then usedfor copy number analysis using Genome Studio plug-
in cnvPartition 3.2 and an R package Genome Alter-
ation Print (GAP) [20]. Inferred copy numbers were
then annotated with genomic features using BedTools
(v. 2.17.0) [21]. Copy number segments of more than
10 Mb in size were classified as arm-level amplifica-
tions and were identified as non-significant alter-
ations. Focal amplifications (less than 10 Mb) were
used for further analysis.
Cytogenetic karyotyping
Cells grown in complete media (60–70 % confluent)
were treated with colcemid (0.1 ng/ul, Sigma, USA) to
arrest them in metaphase. After incubation of 6 h at
37oC and trypsinisation, cells were washed with pre-
warmed KCl (0.075 M) (Sigma, USA) and incubated
with KCl at 37 °C in water bath for 60 min. After the in-
cubation is over, cells were fixed with Carnoy’s fixative
solution on pre chilled microscopic glass slides (chilled
in alcohol) by pipette around 70 μl of cell suspension,
drop by drop from height (50 cm). Slides were kept on
the water bath at 70 °C for few seconds followed by dry-
ing on heating block (set at 80 °C). Metaphase of cells
was confirmed by observing chromosomes using a phase
contrast inverted microscope (Zeiss, USA). Confirmed
metaphase captured cells were aged by keeping the slides
at 60 °C for 3 h followed by trypsin digest (Trypsin/EDTA
- concentration of 0.025 %, Sigma, USA). Giemsa stain
(Sigma, USA) (3 %) was applied using coplin Jar for
15 min on slides followed by washing with distilled water.
Exome sequencing
Exome enrichment was performed using manufacturer’s
protocol for Illumina TruSeq exome enrichment kit in
which 500 ng of DNA libraries from six samples were
pooled to make total 3 μg DNA mass from which
62 MB of targeted exonic region covering 20,976 genes
was captured. Exome enriched library was quantified
and validated by real-time PCR using Kappa quantifica-
tion kit at the Next-Generation Genomics Facility
(NGGF) at Center for Cellular and Molecul ar Platforms
(CCAMP, India). Whole exome libraries of AW13516,
AW8507 and OT9 were loaded onto Illumina HiSeq
1000 for 2 X 100 bp paired-end sequencing with ex-
pected coverage of ~ 100 X. NT8e cell line was se-
quenced with 2 X 54 bp paired-end and 2 X 100 bp
paired-end sequencing. Raw sequence reads generated
were mapped to NCBI human reference genome (build
GRCh37) using BWA v. 0.6.2 [22]. Mapped reads were
then used to identify and remove PCR duplicates using
Picard tools v. 1.74 (http:broadinstitute.github.io/picard/).
Base quality score recalibration and indel re-alignment
were performed and variants were called from each cell
line separately using GATK v. 1.6-9 [23, 24] and MuTect
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dumped into local MySQL database for advanced ana-
lysis and filtering. We used hard filter for removing
variants having below 5X coverage to reduce false
positives. For cell lines we use dbSNP (v. 134) [26] as
standard known germline variants database and COSMIC
(v. 62) [27] as standard known somatic variants database.
Variants identified in cell lines, which are also there in
dbSNP but not in COSMIC were subtracted from the
database. Remaining variants were annotated using
Oncotator (v. 1.0.0.0rc7) [28], and three functional
prediction tools PolyPhen2 (build r394) [29], Provean
(v. 1.1) [30] and MutationAccessor (release 2) [31].
Variants found deleterious by any two out of three
tools were prioritized. Variants having recurrent pre-
diction of deleterious function were prioritized. Vari-
ants from exome sequencing were compared to
variants identified from transcriptome sequencing for
cross-validation using in-house computer program.Transcriptome sequencing
Transcriptome libraries for sequencing were constructed
according to the manufacturer’s protocol. Briefly, mRNA
was purified from 4 μg of intact total RNA using oligodT
beads (TruSeq RNA Sample Preparation Kit, Illumina). 7
pmol of each library was loaded on Illumina flow cell
(version 3) for cluster generation on cBot cluster
generation system (Illumina) and clustered flow cell was
transferred to Illumina HiSeq1500 for paired end se-
quencing using Illumina paired end reagents TruSeq
SBS Kit v3 (Illumina) for 200 cycle. De-multiplexing was
done using CASAVA (version 1.8.4, Illumina). Actively
expressed transcripts were identified from sequencing
data by aligning them to the reference genome hg19
using Tophat (v. 2.0.8b) [32] and quantifying number
of reads per known gene using cufflinks (v.2.1.1)
pipeline [33]. All the transcripts were then binned
by log10(FPKM + 1) to differentiate the significantly
expressed transcripts from the background noise. Since
paired normal of these cell lines cannot be obtained, we
defined significant change in expression for those genes
whose expression is higher (>60 %) or lower (<40 %)
than the median expression as suggested in [34]. Gene
set enrichment was performed by submitting actively
expressed transcripts lists to MSigDB V4 [35] and
filtering resulting gene lists by p-value of enrichment.
Variants were identified from transcriptome sequencing
using GATK [23, 24]. Only variants having overlap with
exome sequencing were considered as true genomic
variants. Fusion transcripts were identified using
ChimeraScan (v.0.4.5) [36]. Candidate fusion events
supported by minimum 10 read pairs were used for
integration and visualization in Circos plot.Integrated analysis
Genes identified to be altered by SNP array, transcriptome
sequencing and exome sequencing were then used for in-
tegrative analysis to prioritize the genes which are har-
bouring multiple types of alteration in same or different
cell line. Gene level converging of genomic data were em-
phasized in identification of biologically relevant alter-
ations across platform and samples. Taking this into
consideration, we designed gene prioritization based on
three steps: 1) selection of genes harbouring positive cor-
relation of focal copy number and gene expression; 2) se-
lection of genes harbouring point mutations with
detectable transcript and or altered copy number, and 3)
selection of genes harbouring multiple type of alter-
ations identified from above two gene lists (Additional
file 1: Figure S7). Circos plot representation of inte-
grated genomics data was generated using Circos tool
(v. 0.66) [37].
Sanger sequencing validation
PCR products were purified using NucleoSpin Gel and
PCR Clean-up kit (MACHEREY-NAGEL) as per manufac-
ture’s protocol and quantified using Nano-Drop 2000c
Spectrophotometer (Thermo Fisher Scientific Inc.) and
submitted for sequencing in capillary electrophoresis 3500
Genetic Analyzer (Life Technologies). Sanger sequencing
traces were analysed for mutation using Mutation
Surveyor [38]. The details of all the primers used for mu-
tation analysis have been provided in Additional file 2:
Table S7.
DNA copy number validation
Quantitative-real time PCR and data analysis was per-
formed using Type-it® CNV SYBR® Green PCR (cat. No.
206674) as per manufacturer’s instructions on 7900HT
Fast Real-Time PCR System. The details of all the
primers used for DNA copy number analysis have been
provided in Additional file 2: Table S8.
RNA extraction, cDNA synthesis, quantitative real time PCR
Total RNA was extracted from cell lines using
RNeasy RNA isolation kit (Qiagen) and Trizol reagent
(Invitrogen) based methods and later resolved on
1.2 % Agarose gel to confirm the RNA integrity. RNA
samples were DNase treated followed (Ambion) by
first strand cDNA synthesis using Superscript III kit
(Invitrogen) and semi-quantitative evaluative PCR for
GAPDH was performed to check the cDNA integrity.
cDNA was diluted 1:10 and reaction was performed
in 10 μl volume in triplicate. The melt curve analysis
was performed to check the primer dimer or non-specific
amplifications. Real-time PCR was carried out using
KAPA master mix (KAPA SYBR® FAST Universal q PCR
kit) as per manufacturer’s instructions in triplicate on
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were repeated at least twice independently. The data was
normalized with internal reference GAPDH, and analysed
by using delta-delta Ct method described previously [39].
The details of all the primers used for expression analysis
have been provided in Additional file 2: Table S8.
Generation of p BABE-NRBP1-PURO constructs
The cDNA of Human NRBP1 was amplified from
AW13516 cell line using Superscript III (Invitrogen,
cat no 18080–093) in a TA cloning vector pTZ57R/
T(InsTAclone PCR cloning kit, K1214, ThermoScientific),
later site-directed mutagenesis was done using QuikChange
II Site-Directed Mutagenesis Kit (cat.no. 200523) as per
manufacturer’s instructions. Later both wild type and
mutant NRBP1 cDNA sequenced confirmed using Sanger
sequencing and were sub-cloned in to retroviral vector
p BABE-puro using restriction digestion based cloning
(SalI and BamHI).
Generation of stable clone of NIH-3 T3 overexpressing
NRBP1
Two hundred ninety-three T cells were seeded in 6 well
plates one day before transfection and each constructs
(pBABE-puro) along with pCL-ECO helper vector were
transfected using Lipofectamine LTX reagent (Invitrogen)
as per manufacturer’s protocol. Viral soup was collected
48 and 72 h post transfection, passed through 0.45 μM
filter and stored at 4 °C. Respective cells for transduction
were seeded one day before infection in six well plate and
allowed to grow to reach 50–60 % confluency. One ml of
the virus soup (1:5 dilution) and 8ug/ml of polybrene
(Sigma) was added to cells and incubated for six
hours. Cells were maintained under puromycin
(Sigma) selection.
shRNA mediated knockdown of NRBP1 in HNSCC cells
We retrieved shRNA sequences targeting human NRBP1
from TRC (The RNAi Consortium) library database lo-
cated in sh1 (3′ UTR) and sh2 (CDS). Target sequences
of NRBP1 shRNA constructs: sh1 (TRCN0000001437),
5′-CCCTCTGCACTTTGTTTACTTCT-3′; sh2 (TRCN0
000001439), 5′-TGTCGAGAAGAGCAGAAGAATCT-3′.
shGFP target sequences is 5′-GCAAGCTGACCCT
GAAGTTCAT-3′. p-LKO.1 GFP shRNA was a gift from
David Sabatini (Addgene plasmid # 30323) [40]. Cloning
of shRNA oligos were done using AgeI and EcoRI restric-
tion site in p-LKO.1 puro constructs. Bacterial colonies
obtained screened using PCR and positive clone were
sequence verified using Sanger sequencing. Lentiviral
production and stable cell line generation performed as
described earlier [41]. In brief, Lentivirus were produced
by transfection of shRNA constructs and two helper vec-
tor in 293 T cells as described [42]. Transduction wasperformed in HNSCC cells by incubating for 6 h in pres-
ence of 10 μg/ml polybrene and post infection media was
replaced with fresh media. Puromycin selection was per-
formed two days post infection in presence of 1 μg/ml.
Puromycin selected cells were harvested and total cell
lysate prepared and expression of NRBP1 was analysed
using anti-NRBP1 antibody (Santa Cruz Biotechnology;
sc-390087) and GAPDH (Santa Cruz Biotechnology;
sc-32233).
Soft Agar colony formation assay
The cells were harvested 48 h after transfection, and
an equal number of viable cells were plated onto soft
agar after respective treatments for determination of
anchorage-independent growth. For analysis of growth
in soft agar, 5 × 103cells were seeded in triplicate onto
a six well dish (Falcon) in 3 ml of complete medium
containing 0.33 % agar solution at 37 °C. Cells were fed
with 500 μl of medium every 2 days. From each well
randomly 10 field images were taken using Phase con-
trast Inverted microscope (Zeiss axiovert 200 m) and
colonies were counted manually.
Growth curve analysis - 25,000 cells/well were seeded
in 24 well plates and growth was assessed post day 2, 4
and 6 by counting the cells using a haemocytometer.
Percent survival were plotted at day 4 relative to day 2
and later normalized against scrambled or empty vector
control.
Western blot analysis
Cells were lysed in RIPA buffer and protein concentra-
tion was estimated using BCA method [43]. 50 and
100 μg protein was used for NIH-3 T3 and HNSCC cell
lines western analysis. The protein was separated on
10 % SDS-PAGE gel, transfer was verified using Ponceau
S (Sigma), transferred on nitrocellulose membrane and
blocked in Tris-buffered saline containing 5 % BSA
(Sigma) and 0.05 % Tween-20(Sigma). Later, blots
were probed with anti-NRBP1 (Santa Cruz Biotechnol-
ogy; sc-390087), anti-total ERK1/2 (Cell signaling;
4372S), anti-Phospho ERK1/2 (Cell signaling; 4370S)
and anti- GAPDH antibody (Santa Cruz Biotechnology;
SC-32233). The membranes were then incubated with
corresponding secondary HRP-conjugated antibodies
(Santa Cruz Biotechnology, USA) and the immune com-
plexes were visualized by Pierce ECL (Thermo Scientific,
USA) according to manufacturer’s protocol. Western blot
experiments were performed as independent replicates.
Statistical analysis
Chi-square and t-test were performed using R program-
ming language and GraphPad Prism. A p-value cut-off
of 0.05 was used for gene expression, copy number and
variant analysis.
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All genomics data have been deposited at the ArrayEx-
press (http://www.ebi.ac.uk/arrayexpress/), hosted by the
European Bioinformatics Institute (EBI), under following
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data; E-MTAB-3961 : Whole exome data; and, E-MTAB-
3960 : SNP array data
Results
We characterized genetic alterations underlying four
head and neck cancer cell lines followed by TCGA data-
set to identify cumulative significance of biologically
relevant alterations by integrating copy number, expres-
sion and point mutation data.
Characterization of four HNSCC cell lines established from
Indian patients
Given that higher accumulative effect of individual genes
can be reckoned by integrative analysis, we argue that
these alteration can possibly be determined even with
fewer samples. As a proof of principle, we performed an
integrated characterization of karyotype analysis, copy
number analysis, whole transcriptome and exome sequen-
cing of 4 HNSCC cell lines established from Indian pa-
tients. In brief, significantly altered chromosomal
segments based on copy number analysis were filtered
based on nucleotide variant information and aberrant ex-
pression of transcripts to allow prioritization of regions
harboring either deleterious mutation or expressing the
transcript at significantly high levels, in addition to the
stringent intrinsic statistical mining performed for each
sample.
Karyotype analysis
The hyperploidy status of AW13516, AW8507, NT8E
and OT9 cell lines were inferred by classical karyotyping
with an average ploidy of 62, 62, 66 and 64, respectively
that were largely consistent with ploidy as inferred form
SNP array analysis (Fig. 1a; Additional file 1: Figure S1)
and as reported for tumor cells lines [18, 19]. We specif-
ically observed dicentric and ring chromosomes at ele-
vated frequency indicating higher chromosomal instability
(CIN) [44]. Overall distribution of chromosomal aberra-
tions in each HNSCC cell lines showed similar pattern,
representing an overall similar genomic structure of all
HNSCC cell lines.
Copy number analysis
We performed genotyping microarray using Illumina
660 W quad SNP array chips of all the cell lines (Additional
file 1: Figure S2). After stringent filtering of initial genotyp-
ing calls, on an average, 253 genomic segments of copy
number changes were obtained per cell line. By limiting
segment size at 10 Mb an average 166 focal segments wereidentified, including loss of copy number and LOH at 3p
which is known to have correlation to advanced stage of
tumor progression and poor clinical outcome [45, 46]; copy
number gain on 11q known to be associated with advanced
stage, recurrence and poor clinical outcome [47]; LOH at
8p and 9p which are known to be associated with advanced
stage and survival [48] (Additional file 2: Table S1); and
amplification of known oncogenes EGFR in AW13516,
OT9; MYC in AW13516 and AW8507 cells; JAK1 in
NT8E, AW8507; NSD1 in AW8507; and MET in
AW13516 and OT9 (Additional file 2: Table S2). Several
hallmark genes were found to be amplified in cell lines such
as CCND1, NOTCH1, and HES1 in all four cells; PIK3CA
in AW13516, AW8507; deletion of CDKN2A in AW13516;
FBXW7 in NT8E, AW13516 and OT9 cells were detected
and validated by real time PCR (Fig. 1b, Additional file 2:
Table S2) in each cell line.
Whole transcriptome analysis
Whole transcriptome sequencing revealed 17,067,
19,374, 16,866 and 17,022 genes expressed in AW13516,
AW8507, NT8e and OT9 respectively. Total ~5000 tran-
scripts having less than 0.1 log10(FPKM + 1) were filtered
out because of biologically non-significant expression
level (Additional file 1: Figure S3). The upper quartile
(>60 %) was considered as highly expressed genes and
lower quartile (<40 %) was considered as lowly expressed
genes. Gene set enrichment analysis of upper quartile
showed enrichment of genes (data not shown) known to
be up regulated in nasopharyngeal carcinoma [49]. All
the transcripts showed 75 % overlap of expression profile
with each other (Additional file 1: Figure S4) indicating
overall similar nature of cell lines. Over expression of
hallmark of HNSCC such as CCND1, MYC, MET,
CTNNB1, JAK1, HRAS, JAG1, and HES1 and down
regulation of FBXW7, SMAD4 in at least 3 cell line were
observed and validated by quantitative real time PCR
(Additional file 2: Table S3). A positive correlation was
observed between transcriptome FPKM and qPCR Ct
values (Fig. 1c).
Analysis of mutational landscape
All the cell lines were sequenced for whole exome at
about 80X coverage using Illumina HiSeq. The relative
coverage of each coding region was comparable across
all four cell lines (Additional file 2: Table S4; Additional
file 1: Figure S5). The coding part of the four cell line
genome consist 28813, 47892, 20864 and 25029 variants
in AW13516, AW8507, NT8e and OT9 cell line, re-
spectively. Filtering of known germline variants (SNPs)
and low quality variants left 5623, 4498, 2775, 5139 non-
synonymous variants in AW13516, AW8507, NT8e and
OT9 cell line, respectively (Additional file 2: Table S4).
Of 20 HNSCC hallmark variants predicted as deleterious
Fig. 1 Genomic alterations identified in HNSCC cell lines. a Chromosomal aberrations identified by 25 independent karyotype of each cell line is
represented in circular form. Chromosome numbers in each cell line are indicated by n, as observed from karyotype (*) and predicted by SNP
array (^). b Heatmap representation of copy number changes in key hallmark genes identified by SNP array and validated by qPCR. Grey box
indicates validated and white box indicates invalidated copy number change in respective cell line. c Scatter plot representation of hallmark
gene’s expression. X-axis shows gene expression quantified by RNA sequencing and Y-axis shows gene expression quantified by RT-qPCR. Genes
showed positive correlation between RNA sequencing and RT-qPCR. d Several high-quality point mutations identified by exome sequencing were
validated by Sanger sequencing. Sanger sequencing trace were visualized using Mutation Surveyor software showing reference sequence trace in upper
panel and mutant sequencing trace in below panel. Arrows represent mutation position with reference and mutated base indicated above the arrow
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[29–31], 17 variants could be validated by Sanger se-
quencing (Fig. 1d; Additional file 2: Table S5) including:
TP53 (R273H), TP53 (P72R), PTEN (H141Y), EGFR
(R521K), HRAS (G12S and R78W), and CASP8 (G328E).
Integrated analysis identifies hallmark alterations in
HNSCC cell lines
The first step of integration analysis involved identifica-
tion of genes with positively correlated copy number
and expression data. While no significant correlation
was observed among expression and arm-level copy
number segments (Additional file 1: Figure S6a), me-
dian expression of focally amplified and deleted genespositively correlated to their expression (Fig. 2a and
Additional file 1: Figure S6b). About 1000 genes with
focal copy number changes with consistent expression
pattern were identified from four cell lines. The second
step of integration analysis involved identification of mu-
tated genes that were expressed. Number of missense mu-
tations identified from transcriptome sequencing (67,641
variants) were much higher than from exome sequencing
(30,649 variants). Filtering of exome variants against tran-
scriptome variants reduced total number of 9253 unique
missesne variants in all four cell lines (Fig. 2b). Two thou-
sand four hundred seventy-nine missense mutations of
9523 total mutations found across all cells were used for
further integration with copy number and expression data
Fig. 2 Integration of copy-number, gene expression and single nucleotide variants. a Box plot representations showing focal copy number variations
identified by SNP array on X-axis and gene expression quantified by RNA sequencing on Y-axis. Focally amplified or deleted genes from all four cell
lines showed a positive trend with over expression or under expression respectively. b Scatter plot representation of genes harboring single nucleotide
variants and it’s expression from all four cell lines. Variants identified by whole exome sequencing are displayed by genomic coordinates on X-axis and
normalized quantity of gene expression (by transcriptome sequencing) is displayed on Y-axis. Red line denotes 0.01 log10(FPKM + 1) filter which
removes ~50 % of the total variants
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gration, we sorted genes with altered copy number, ex-
pression levels and harboring non-synonymous mutations
for integrated analysis based on criterion as described in
methodology in four cell lines (Additional file 1: Figure S7).
Briefly, genes harbouring two or more type of alterations
were selected: harbouring positive correlation of focal copy
number and gene expression; or those harbouring point
mutations with detectable transcript harbouring the var-
iant—based on which, we identified 38 genes having mul-
tiple types of alterations (Additional file 2: Table S6). These
include genes known to have somatic incidences in
HNSCC: TP53, HRAS, MET and PTEN. We also identified
CASP8 in AW13516 cell line which was recently identified
as very significantly altered by ICGC-India team in ~50 In-
dian HNSCC patients [50]. We additionally identified novel
genes like CCNDBP1, GSN, IMMT, LAMA5, SAT2 and
WDYHV1 to be altered by all three analysis i.e. CNV, ex-
pression and mutation. These all genes were also found to
be altered in TCGA dataset with minimum 3 % cumulative
frequency (Additional file 1: Figure S8). The overall conver-
gence of copy number, expression and mutation data in
each cell line is represented as circos plot (Fig. 3a;
Additional file 1: Figure S9). Among the novel genes identi-
fied, of genes with at least one identical mutation previously
reported include a pseudokinase Nuclear receptor binding
protein NRBP1 harboring heterozygous truncating muta-
tion (Q73*) in NT8e cells, identical to as reported in lung
cancer and altered in other cancers [51, 52].
Mutant NRBP1 is required for tumor cell survival and is
oncogenic in NIH3T3 cells
NRBP1 encodes for three different nuclear receptor
binding protein isoform using three alternative transla-
tional initiation sites of 60 kDa, 51 kDa and 43 kDa [53],as were observed in 2 of 3 HNSCC cells (Fig. 4a). To de-
termine whether expression of mutant NRBP1 is re-
quired for tumor cell survival, we tested shRNA
constructs in two HNSCC cells expressing all three
forms of WT NRBP1 (OT9 cells) and mutant NRBP1
(NT8e cells). We demonstrate that even partial knock-
down of mutant NRBP1 expression in the NT8e cells,
but not WT NRBP1 expression in the OT9, significantly
inhibited anchorage-independent growth and cell sur-
vival (Fig. 4b–d). We next tested the oncogenic role of
NRBP1. mRNAs harboring premature termination
(nonsense) codons are selectively degraded by
Nonsense-mediated mRNA decay (NMD) [54]. How-
ever, mRNAs with nonsense mutations in the first exon
are known to bypass NMD [55]. When ectopically
expressed in NIH-3 T3 cells, mutant NRBP1 transcript
escape non-sense mediated degradation as determined
by real time PCR (Additional file 1: Figure S10). All
three isoform of NRBP1 were detected in NIH-3 T3
cells expressing wild type NRBP1 cDNA. However, only
two isoform of 51 kDa and 43 kDa were detected in cells
transfected with mutant NRBP1 cDNA (Fig. 4e upper
panel). The over expression of the mutant NRBP1 in
NIH3T3 cells conferred anchorage-independent growth,
forming significantly higher colonies in soft agar than
cells expressing wild type NRBP1 (Fig. 4f ). Transform-
ation of NIH-3 T3 cells by NRBP1 over expression
was accompanied by elevated phosphorylation of the
MAPK (Fig. 4e lower panel).
Integrated analysis of TCGA dataset for HNSCC hallmark
genes
Next, as a proof of principle, we computated cumulative
frequency of copy number variations, expression
changes and point mutations across 43 genes with ~3 %
Fig. 3 Integrative genomic landscape of HNSCC. a Circos plot representations of genes identified by integrated genomic analysis of HNSCC cell lines.
From outside to inside: karyotype, CNVs, Gene expression (FPKM), SNVs and translocations. Red colour indicates copy number gain or higher gene
expression and blue colour indicates copy number loss or lower gene expression in CNV and FPKM tracks respectively. Non-synonymous mutations
are indicated as blue triangles and grey circles represents non-sense mutations in SNV track. Fusion transcripts identified by transcriptome sequencing
are shown as arc coloured by their chromosome of origin identified by ChimeraScan. b Heatmap representation of novel genes identified
by integrated analysis of four HNSCC cell lines and their incidence in 279 HNSCC samples from TCGA study. Amplification (red) and
deletions (blue) are indicated by filled box, over expression (red) and under expression (blue) are indicated by border line to the box,
mis-sense (green), non-sense (black) and in-frame (brown) mutations are indicated by smaller square box
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set. As expected and described for few genes [4, 56],
most of the genes were found to be altered at higher cu-
mulative incidence than as reckoned by individual alter-
ations (Fig. 5). Interestingly, three class of hallmark
genes involved in HNSCC could be distinctly identified:
genes that are primarily altered by mutations like TP53
and SYNE1; genes that are sparsely altered by amplifica-
tion or overexpression in addition to mutations like
FAT1, NOTCH1, KMT2D, and FLG; and, genes that are
preferentially altered by amplification or over expression
over point mutations with higher cumulative effect than
known before. Of these, previously described genes like
PIK3CA, CDKN2A, TP63, EGFR, CASP8, NFE2L2, and
KRAS show more than twice cumulative effect of alter-
ation while rest of the genes are altered at several folds
higher cumulative frequency based on integrated ana-
lysis. Furthermore, three genes– UBR5, ZNF384 and
TERT were found to be altered with cumulative fre-
quency of 32, 19, and 16 %, respectively that has not
been previously described in HNSCC.Discussion
We have characterized genetic alterations of unknown
somatic status underlying four head and neck cancer cell
lines of Indian origin patient by subjecting them to a
thorough karyotype based characterization, SNP array
based analysis, whole exome capture sequencing, and
mRNA sequencing.
Integrated analysis of the cell lines establish their re-
semblance to primary tumors. Consistent with literature,
most frequent copy number gains in head and neck can-
cer cells in this study were observed at 2q, 3q, 5p and
7p, and deletions at 3p, 9p, 10p, 11q, 14q, 17q and 19p,
as reported earlier [57, 58]. Integration of multiple plat-
form with the copy number variation, allowed us to
identify the functionally relevant alterations including
several hall marks genes known to be involved in
HNSCC, viz. PIK3CA, EGFR, HRAS, MYC, CDKN2A,
MET, TRAF2, PTK2 and CASP8. Of the novel genes,
JAK1 was found to be amplified in two of the cell lines
and overexpressed in all 4 HNSCC cells; NOTCH1 known
to harbor inactivating mutations in HNSCC [3, 50] was
Fig. 4 Mutant NRBP1 is required for tumor cell survival and is oncogenic in NIH3T3 cells. Knockdown of mutant NRBP1 expression with shRNA inhibits
transformation and survival of HNSCC cell lines. a Western blot analysis of total NRBP1 expression level in HNSCC cell lines. NRBP1 encodes for three
different nuclear receptor binding protein isoform: 60 kDa, 51 kDa and 43 kDa in NT8e cells (lane 1), OT9 cells (lane 2). AW13516 cells express only two
isoforms (lane 3). b Western blot representation of NRBP1 partial knockdown by two independent hairpins (shNRBP1#1 and shNRBP1#2) in NT8e and
OT9 cells. The hairpin constructs inhibit cell survival as assessed by cell counting as described in methods. c and anchorage-independent growth as
assessed by colony formation in soft agar d in the NT8e cells harboring an NRBP1 Q73* mutation, but not the OT9 cells, which express WT NRBP1.
shGFP, a hairpin specific for green fluorescent protein, was used as a negative control. All results are normalized to survival or colony formation by cells
infected with empty vector. Images were taken at 10X magnification. e Western blot analysis of NRBP1 wild type and mutant (Q73*) in NIH-3 T3 cells.
Vector control, NIH-3 T3 clones overexpressing wild-type and mutant NRBP1 is shown. NRBP1 Q73* mutation expresses 51 kDa isoform, while two
isoform of 60 kDa and 51 kDa can be seen in 3 T3 clones overexpressing wild-type NRBP1. Western blot analysis of total and phosphorylated MAPK in
NIH-3 T3 clones expressing NRBP1 wild type (lane 2) and mutant NRBP1 (Q73*). f Representative images (taken at 20x) of soft agar colony formed by
NIH-3 T3 cells expressing NRBP1 wild type and Q73*. Bar graph representation of number of soft agar colonies formed by stable NIH-3 T3 clones.
NIH-3 T3 cells expressing EGFR VIII was used as positive control and relative comparison of transforming ability of mutant NRBP1. *** P-value <0.0001,
** P-value <0.001
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HNSCC cells, known to be play dual role in a context
dependent manner [59].
We also observed missense mutations in several novel
genes such as CLK2, NRBP1, CCNDBP1, IDH1, LAMA5,
BCAR1, ZNF678, and CLK2. Of these, genes with at least
one identical mutation previously reported include NRBP1
(Q73*), a pseudo kinase, found in NT8e cells, earlier re-
ported in lung and other cancers [51, 52], with an overall
9 % cumulative frequency alteration in TCGA HNSCC
dataset (Additional file 1: Figure S8). Of 48 pseudo kinases
known in human genome, several have been shown to re-
tain their biochemical catalytic activities despite lack of one
or more of the three catalytic residues essential for its kin-
ase activity, with their established roles in cancer [60–62].Interestingly, several activating mutant alleles of
NRBP1 homolog Drosophila Madm (Mlf1 adapter mol-
ecule) 3 T4 (Q46*); 2U3 (C500*); 3G5 (Q530*); 7 L2 and
3Y2 (that disrupts splice donor site of first exon) are
known, wherein alternative translation start codons is
similarly suggestive for a varying degree of pinhead pheno-
type severity associated with the mutant alleles [53, 63].
Studies in the fruit fly have provided important insights into
mechanisms underlying the biology of growth promoting
NRBP1 homolog Drosophila Madm. A recent study sug-
gests Drosophila Madm interacts with Drosophila bunA
that encodes a gene homologous to human Transforming
Growth Factor-β1 stimulated clone-22 TSC-22 [63]; that
were later shown to interact even in mammalian system
[64]. Interestingly, mammalian tumor suppressor TSC-22 is
Fig. 5 Integrative genomic landscape of HNSCC tumors in TCGA dataset. Heatmap representation of hallmark genes in 279 HNSCC samples from
TCGA study with frequency of alterations based on integrated CNVs, gene expression and SNVs. Frequency of alterations in the gene based on
Cosmic database, Agrawal et al., Stransky et al. and TCGA study are also shown for comparison with integrated analysis. Amplification (red) and
deletions (blue) are indicated by filled box, over expression (red) and under expression (blue) are indicated by border line to the box, mis-sense
(green), non-sense (black) and in-frame (brown) mutations are indicated by smaller square box
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ated phenotype in salivary gland tumors [65], a subtype of
head and neck cancer. More recently, studies have shown
poor clinical outcomes are associated with NRBP1 over
expression in prostate cancer [64]. We provide the first
functional analysis of mutant NRBP1 and establish that
NIH-3 T3 cells expressing the mutant NRBP1 enhance
their survival and anchorage independent growth, while
its knock down diminishes survival and anchorage-
independent growth by oral cancer cells expressing
activating NRBP1 mutations. Thus, NT8e cells harboring
mutant NRBP1 was found to be consistent with its
suggestive role in prostate cancer biology and other model
organisms. Interestingly, NRBP1 has also been shown to
be involved in intestinal progenitor cell homeostasis with
tumor suppressive function [66], suggesting its role is spe-
cific to the cellular context. This study identifies NRBP1
mutant to play an oncogenic role in head and neck cancer.
However, in depth systematic sequencing of NRBP1 in a
wide variety of tumor types may help indicate utility of
NRBP1 inhibition in human cancer.
Furthermore, based on TCGA data integrated analysis,
cumulative alteration frequency of TP63 (35 %), EGFR
(23 %) and NFEL2 (19 %) were found to be higher than
reported in COSMIC and cBioPortal, consistent with as
described in other reports [4, 56]. Of alterations notdefined before, UBR5, ZNF384 and TERT were found
to be altered at higher frequency at 32, 19, 16 %, re-
spectively. Interestingly, recurrent UBR5-ZNF384 fusion
has been shown to be oncogenic in EBV-associated
nasopharyngeal subtype of HNSCC [67]; amplification
of TERT has been shown to be higher in lung squa-
mous [68], suggesting these alterations as potential
squamous specific event, though that warrants detailed
systematic assessment.
In overall, this study underscores integrative approaches
through a filtering strategy to help reckon higher cumula-
tive frequency for individual genes affected by two or
more alterations to achieve the threshold for statistical
significance even from fewer samples. The integrative
analysis as described here, in essence, is based on a linear
simplified assumption of disease aetiology that variation at
DNA level lead to changes in gene expression causal to
transformation of the cell. As a major deficiency, only
genes that are subject to multiple levels of biological regu-
lation are likely to be determined by this approach than
genes that are primarily altered by single alteration like
amplification or over expression.
Conclusion
As a proof of principle, integrated analysis of copy
number variation, exome and transcriptome of 4 head
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set identify NRBP1, UBR5, ZNF384 and TERT as
novel candidate oncogenes in HNSCC. However, sys-
tematic functional experimental validation is required
to further guide and identify true driver events of
these alterations. Additionally, the genetically- defined
cellular systems characterized by integrated genomics
analysis in this study (NT8e, OT9, AW13516, AW8507),
together with the identification of novel actionable mo-
lecular targets, may help further facilitate the pre-clinical
evaluation of emerging therapeutic agents in head and
neck cancer.
Additional files
Additional file 1: Additional Figures S1-S10. Chromosomal aberration
in HNSCC patient derived cell lines AW8507, AW13516, NT8e and OT9.
(A) Representative karyotype of AW8507, AW13516, NT8e and OT9 cells is
shown from total 25 karyotypes obtained per cell line. (B) Chromosomal
aberrations identified by 25 independent karyotype of each cell line is
represented in circular form. Chromosome numbers in each cell line are
indicated by n, as observed from karyotype (*) and predicted by SNP
array (^). Copy number changes in HNSCC cell lines identified by SNP
array. Genome alteration print (GAP) of (A) AW8507, (B) AW13516, (C)
NT8e AND (D) OT9 cell lines obtained by SNP array. First horizontal block
represents B-allele frequency, second block represents absolute copy
number, third block is log R ratio. Frequency of transcripts per binned log
transformed FPKM + 1. Raw RNA sequencing data was binned to obtain
frequency of genes per log10(FPKM + 1) in (A) AW8507, (B) AW13516,
(C) NT8e and (D) OT9. Horizontal dotted lines indicates percentile of
transcripts in the quadrant. Similarity of gene expression in HNSCC cell
lines. Number of genes commonly expressed between AW8507, AW13516,
NT8e and OT9 cell lines. Relative depth in exome sequencing. Relative
depth of sequencing for various genomic regions in (A) AW8507, (B)
AW13516, (C) NT8e and (D) OT9. Correlation of copy number with gene
expression. (A) Arm level and (B) focal copy number changes and gene
expression (y-axis) are shown for AW8507, AW13516, NT8e and OT9 cell
lines. Correlation of focal copy number with gene expression was 1.5
fold higher in AW8507, 5.2 fold higher in AW13516, 2.4 fold higher in
NT8e and 1.6 fold higher in OT9 cell line compare to arm level copy number
changes. P-value cut-off of 0.05 was used as threshold for statistical signifi-
cance.* denotes P-value <0.05, ** <0.005, *** <0.0005. Schematic view of data
reduction in integrated genomic analysis. Flow chart depicts the reduction of
data at each stage of integration. First row indicates number of genes identi-
fied from each platform as raw calls. Second and third row indicates number
of genes left after each step of integration with main selection parameter
indicated outside the box. Integrative genomic alterations of genes in TCGA
dataset of HNSCC tumors. Heatmap representation of 38 genes in 279 HNSCC
samples from TCGA study with frequency of alterations based on integrated
CNVs, gene expression and SNVs. Amplification (red) and deletions (blue) are
indicated by filled box, over expression (red) and under expression (blue) are
indicated by border line to the box, mis-sense (green), non-sense (black) and
in-frame (brown) mutations are indicated by smaller square box. Circos plot
representation of HNSCC cell lines. Circos plot representations of integrated
genomic data of (A) AW8507, (B) AW13516, (C) NT8e and (D) OT9 cell lines.
From outside to inside: karyotype, CNVs, Gene expression (FPKM), SNVs
and translocations. Red colour indicates copy number gain or higher gene
expression and blue colour indicates copy number loss or lower gene
expression in CNV and FPKM tracks, respectively. Non-synonymous mutations
are indicated as blue triangles and grey circles represents non-sense mutations
in SNV track. Fusion transcripts identified by transcriptome sequencing are
shown as arc coloured by their chromosome of origin identified by
ChimeraScan. NRBP1 expression in NIH-3 T3 cells. qPCR analysis of NRBP1
gene expression in NIH-3 T3 stably expressing wild and mutant. Data was
normalized against GAPDH and fold change plotted. P value <0.0001 is
denoted as ***. (PDF 9017 kb)Additional file 2: Additional Tables S1-S8: Copy number alterations of
known genomic locations identified in HNSCC cell lines. Copy number
alterations in halmark genes identified in HNSCC cell lines. Gene
expression of hallmark genes by RNA sequencing and qPCR. Features
of whole exome and transcriptome sequencing. Validation of mutations
in hallmark and novel genes. Details of mutations identified by integrated
analysis in HNSCC cell lines. Primer sequences used for Sanger sequenicng
based validation of mutations. Primers used for copy number and gene
expression study using qPCR. (ZIP 249 kb)
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